Johnson Johnson JNJ Icotyde Partnership Drives Portfolio Expansion and DeRisked Biotech Upside RFAI RF outlines upcoming strategic acquisition targets in its latest quarterly earnings release OSPN OneSpan delivers 20 percent Q4 2025 EPS beat shares rise modestly on upbeat investor reception